Holen Sie sich die Stockscreener-App
3.175
5.01%
0.155
Ventyx Biosciences Inc Aktie (VTYX) Neueste Nachrichten
Ventyx Biosciences Inc. Stock Analysis and ForecastTremendous wealth creation - Autocar Professional
What analysts say about Ventyx Biosciences Inc. stockAccelerated earnings growth - jammulinksnews.com
Is Ventyx Biosciences Inc. a good long term investmentTremendous return rates - jammulinksnews.com
Why Ventyx Biosciences Inc. stock attracts strong analyst attentionSmart Return Focused Trading - Newser
Is Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Invest In Growth? - Yahoo Finance
What drives Ventyx Biosciences Inc. stock priceFree Stock Market Real-Time Monitoring - jammulinksnews.com
What makes Ventyx Biosciences Inc. stock price move sharplyFree Insider Trading Tips - Newser
How Ventyx Biosciences Inc. stock performs during market volatilityAlpha Stock Ideas - Newser
Wealth Enhancement Advisory Services LLC Invests $28,000 in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
Ventyx Biosciences (VTYX) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
Analyzing the Impact of Earnings Reports on Ventyx Biosciences Inc Inc. (VTYX) Price Performance - investchronicle.com
Class Action Filed Against Ventyx Biosciences, Inc. (VTYX)April 30, 2024 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Ventyx Biosciences, Inc. (VTYX) Shareholders - ACCESS Newswire
Ventyx Biosciences, Inc.(NasdaqGS: VTYX) dropped from Russell 3000E Index - MarketScreener
Ventyx Biosciences, Inc.(NasdaqGS: VTYX) dropped from Russell 3000 Value Index - MarketScreener
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Shares Sold by Rhumbline Advisers - Defense World
Canaccord maintains buy rating on Ventyx stock after positive trial results - Investing.com
Ventyx stock steady as Parkinson’s drug shows biomarker reductions By Investing.com - Investing.com India
Ventyx reports positive outcomes from trial of VTX3232 for Parkinson’s - Yahoo Finance
Ventyx Therapeutics' VTX3232: A Neuroinflammation Breakthrough with Orphan Drug Pricing Power - AInvest
Ventyx Biosciences Inc’s Mixed Bag: Down -9.22% in 6 Months, Down 58.21% in 30 Days - investchronicle.com
Ventyx Biosciences Holds Steady Despite Encouraging Early Parkinson’s Trial Results - MSN
Ventyx Biosciences Announces Positive Top-Line Data from - GlobeNewswire
Ventyx Biosciences Shares Fall After Tier 2 Exploratory Biomarkers Remain Stable in Parkinson's Study - MarketScreener
Ventyx reports positive Phase 2a results for Parkinson’s drug - Investing.com
Ventyx Biosciences Insiders Placed Bullish Bets Worth US$1.26m - Yahoo.co
Ventyx Biosciences' Study of VTX3232 Met Safety, Tolerability Objectives - MarketWatch
Ventyx posts mid-stage trial win for Parkinson’s drug (VTYX) - Seeking Alpha
Ventyx Biosciences stock trades flat despite positive parkinson’s drug trial data - Investing.com Canada
Ventyx Biosciences Announces Positive Data From Its Phase 2A Trial Evaluating Vtx3232 In Patients With Early-Stage Parkinson'S Disease - marketscreener.com
Ventyx Biosciences Announces Positive Data From Its Phase 2A Trial Evaluating Vtx3232 In Patients With Early-Stage Parkinson’S Disease - TradingView
Ventyx reports positive Phase 2a results for Parkinson’s drug By Investing.com - Investing.com India
VTYX Trading Halted as Market Awaits News Update | VTYX Stock News - GuruFocus
Piper Sandler maintains $21 target on Ventyx stock By Investing.com - Investing.com Nigeria
Traders Buy Large Volume of Ventyx Biosciences Call Options (NASDAQ:VTYX) - Defense World
Ventyx Biosciences reports annual meeting results By Investing.com - Investing.com India
4.47%
0.27%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):